-       Report 
   - November 2025
    -  50 Pages 
    Global
   
   From       €2382EUR$2,650USD£2,089GBP 
                  -       Drug Pipelines 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1079EUR$1,200USD£946GBP 
      €1348EUR$1,500USD£1,182GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1079EUR$1,200USD£946GBP 
      €1348EUR$1,500USD£1,182GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1079EUR$1,200USD£946GBP 
      €1348EUR$1,500USD£1,182GBP 
                -       Report 
   - May 2023
    -  94 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                 -       Report 
   - March 2025
    -  109 Pages 
    China
   
   From       €1618EUR$1,800USD£1,419GBP 
                -       Report 
   - March 2025
    -  215 Pages 
    China
   
   From       €3595EUR$4,000USD£3,153GBP 
                      Nimodipine is a calcium channel blocker used to treat high blood pressure and other cardiovascular conditions. It is used to reduce the risk of stroke in patients with a history of transient ischemic attack (TIA) or ischemic stroke. Nimodipine is also used to reduce the risk of complications from subarachnoid hemorrhage, a type of stroke caused by bleeding in the brain. Nimodipine is available in oral and intravenous formulations.
Nimodipine is a widely used drug in the cardiovascular market. It is    used to treat hypertension, angina, and other cardiovascular conditions. It is also used to reduce the risk of stroke in patients with a history of TIA or ischemic stroke. Nimodipine is generally well tolerated and has few side effects.
In the Nimodipine market, there are several companies that manufacture and distribute the drug. These include Pfizer, Novartis, Sanofi, Merck, and GlaxoSmithKline. Show Less   Read more